Delaware – September 2020, iQure Pharma Inc. (iQure), a company dedicated to preclinical and early clinical development of new therapeutics, secured an additional funding of $100 000.
We are pleased to confirm that we have secured funding of $100,000 as a convertible loan from Dr Beat Widler, company Director and member of the iQure Management team. Under the agreement, iQure will deploy proceeds to continue its business operations and support fundraising activities especially for our Neuropathic Pain compounds iQ-007 and iQ‑008.
Pawel Zolnierczyk, Chief Executive Officer:
We are delighted that Dr Widler has decided to invest in iQure Pharma. This investment represents a high level of trust in our business and its ongoing development. Part of the secured funding will allow iQure to co-invest with prospective investors in our Neuropathic Pain portfolio. Here at iQure Pharma, we are looking for promising new therapeutics to develop that will help patients suffering from Neuropathic Pain.